[go: up one dir, main page]

AR075447A1 - Sales y polimorfos de un compuesto de tetraciclina, metodo de obtencion y composiciones farmaceuticas - Google Patents

Sales y polimorfos de un compuesto de tetraciclina, metodo de obtencion y composiciones farmaceuticas

Info

Publication number
AR075447A1
AR075447A1 ARP090101875A ARP090101875A AR075447A1 AR 075447 A1 AR075447 A1 AR 075447A1 AR P090101875 A ARP090101875 A AR P090101875A AR P090101875 A ARP090101875 A AR P090101875A AR 075447 A1 AR075447 A1 AR 075447A1
Authority
AR
Argentina
Prior art keywords
compound
crystalline
solution
salt
salts
Prior art date
Application number
ARP090101875A
Other languages
English (en)
Inventor
Tadeusz Warchol
Raymond Cvetovich
Original Assignee
Paratek Pharm Innc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paratek Pharm Innc filed Critical Paratek Pharm Innc
Publication of AR075447A1 publication Critical patent/AR075447A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C07C237/26—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton of a ring being part of a condensed ring system formed by at least four rings, e.g. tetracycline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y20/00—Nanooptics, e.g. quantum optics or photonic crystals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/32—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B6/00—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings
    • G02B6/10—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type
    • G02B6/12—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type of the integrated circuit kind
    • G02B6/122—Basic optical elements, e.g. light-guiding paths
    • G02B6/1223—Basic optical elements, e.g. light-guiding paths high refractive index type, i.e. high-contrast waveguides
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B6/00—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings
    • G02B6/10—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type
    • G02B6/12—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type of the integrated circuit kind
    • G02B6/13—Integrated optical circuits characterised by the manufacturing method
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
    • C07C2603/42—Ortho- or ortho- and peri-condensed systems containing four condensed rings containing only six-membered rings
    • C07C2603/44—Naphthacenes; Hydrogenated naphthacenes
    • C07C2603/46—1,4,4a,5,5a,6,11,12a- Octahydronaphthacenes, e.g. tetracyclines
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B6/00—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings
    • G02B6/10—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type
    • G02B6/12—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type of the integrated circuit kind
    • G02B2006/12035—Materials
    • G02B2006/12038—Glass (SiO2 based materials)
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B6/00—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings
    • G02B6/10—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type
    • G02B6/12—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type of the integrated circuit kind
    • G02B2006/12083—Constructional arrangements
    • G02B2006/12119—Bend
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B6/00—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings
    • G02B6/24—Coupling light guides
    • G02B6/26—Optical coupling means
    • G02B6/28—Optical coupling means having data bus means, i.e. plural waveguides interconnected and providing an inherently bidirectional system by mixing and splitting signals
    • G02B6/2804—Optical coupling means having data bus means, i.e. plural waveguides interconnected and providing an inherently bidirectional system by mixing and splitting signals forming multipart couplers without wavelength selective elements, e.g. "T" couplers, star couplers
    • G02B6/2861—Optical coupling means having data bus means, i.e. plural waveguides interconnected and providing an inherently bidirectional system by mixing and splitting signals forming multipart couplers without wavelength selective elements, e.g. "T" couplers, star couplers using fibre optic delay lines and optical elements associated with them, e.g. for use in signal processing, e.g. filtering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Nanotechnology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • General Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proveen formas cristalinas, incluyendo sales y polimorfos, de un compuesto util en el tratamiento de estados que responden a la tetraciclina. Los compuestos cristalinos son utiles para el tratamiento o prevencion de condiciones y desordenes tales como infecciones bacterianas y neoplasmas, como también otras aplicaciones conocidas de compuestos de tetraciclina en general. Reivindicacion 1: Una forma cristalina del compuesto 1. Reivindicacion 2: Una sal de tosilato del compuesto 1. Reivindicacion 3: Una forma cristalina de la sal de la reivindicacion 2. Reivindicacion 4: Un polimorfo de la forma cristalina de la reivindicacion 3, caracterizado porque tiene un patron de difraccion de polvo por rayos X sustancialmente similar al expuesto en la figura 8. Reivindicacion 9: Un método para preparar una sal de tosilato cristalina estable del compuesto 1 caracterizado porque comprende disolver una base libre del compuesto 1 en un primer solvente o combinacion de solventes para formar una primera solucion; disolver ácido p-toluensulfonico en un segundo solvente o combinacion de solventes para formar una segunda solucion; y combinar dicha primera y segunda solucion para formar una tercera solucion. Reivindicacion 27: Una composicion farmacéutica caracterizada porque comprende una sal cristalina de la reivindicacion 3 y un diluyente, excipiente o portador farmacéuticamente aceptable.
ARP090101875A 2008-05-19 2009-05-26 Sales y polimorfos de un compuesto de tetraciclina, metodo de obtencion y composiciones farmaceuticas AR075447A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12871208P 2008-05-19 2008-05-19

Publications (1)

Publication Number Publication Date
AR075447A1 true AR075447A1 (es) 2011-04-06

Family

ID=41340587

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090101875A AR075447A1 (es) 2008-05-19 2009-05-26 Sales y polimorfos de un compuesto de tetraciclina, metodo de obtencion y composiciones farmaceuticas

Country Status (30)

Country Link
US (4) US8383610B2 (es)
EP (3) EP2807926B1 (es)
JP (7) JP5727930B2 (es)
KR (1) KR101679362B1 (es)
CN (4) CN102105058B (es)
AR (1) AR075447A1 (es)
AU (2) AU2009248795B2 (es)
BR (1) BRPI0913026B1 (es)
CA (2) CA2987354A1 (es)
CO (1) CO6300898A2 (es)
CY (2) CY1116436T1 (es)
DK (2) DK2807926T3 (es)
EC (1) ECSP10010704A (es)
ES (2) ES2842204T3 (es)
HR (2) HRP20150584T1 (es)
HU (1) HUE053038T2 (es)
IL (1) IL209414A0 (es)
LT (1) LT2807926T (es)
MA (1) MA32407B1 (es)
MX (1) MX2010012622A (es)
MY (1) MY156254A (es)
NZ (2) NZ598154A (es)
PL (2) PL2296464T3 (es)
PT (2) PT2807926T (es)
RU (1) RU2500665C2 (es)
SI (2) SI2807926T1 (es)
TN (1) TN2010000539A1 (es)
TW (6) TW202332671A (es)
WO (1) WO2009143509A1 (es)
ZA (2) ZA201008390B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2216323A3 (en) * 2007-04-27 2010-12-29 Paratek Pharmaceuticals, Inc. Methods for synthesizing and purifying aminoalkyl tetracycline compounds
BRPI0908951A2 (pt) 2008-03-05 2017-01-17 Paratek Pharm Innc compostos de minociclina e método de uso dos mesmos
TW202332671A (zh) * 2008-05-19 2023-08-16 美商Ｐｒｔｋ Ｓｐｖ２公司 四環素化合物之甲苯磺酸鹽及同素異形體
LT2707003T (lt) * 2011-05-12 2019-10-10 Paratek Pharmaceuticals, Inc. Kristalinės (4s,4as,5ar,12as)-4-dimetilamino-3,10,12,12a-tetrahidroksi-7-[(metoksi(metil)amino)-metil]-1,11-diokso-1,4,4a,5,5a,6,11,12a-oktahidro-naftacen-2-karboksirūgšties amido druskos ir jų panaudojimo būdai
PT108223B (pt) 2015-02-13 2018-05-08 Hovione Farm S A Novas formas polimórficas de minociclina base e processos para a sua preparação
SG11201707784XA (en) 2015-03-23 2017-10-30 Biopharmx Inc Pharmaceutical tetracycline composition for dermatological use
SG11201808246SA (en) * 2016-03-24 2018-10-30 Paratek Pharm Innc Methods for treating and preventing c. difficile infection
US10238670B2 (en) * 2016-05-02 2019-03-26 Paratek Pharmaceuticals, Inc. 9-aminomethyl minocycline compounds and methods of use thereof in urinary tract infection (UTI) treatment
MX381701B (es) * 2016-06-22 2025-03-13 Kbp Biosciences Co Ltd Formas cristalinas de un compuesto de tetraciclina sustituido con 9-aminometilo y un metodo para la preparacion de las mismas
TWI746610B (zh) * 2016-08-03 2021-11-21 美商派瑞泰Ｓｐｖ２有限公司 9-胺甲基米諾四環素化合物及其用途
SG11201902599SA (en) * 2016-10-03 2019-05-30 Brivention Pharmaceutical Shanghai Inc Composition comprising combination of trh analog with arundic acid, and pharmaceutically acceptable salt of arundic acid
US10961190B2 (en) * 2016-10-19 2021-03-30 Tetraphase Pharmaceuticals, Inc. Crystalline forms of eravacycline
SG10201913599RA (en) 2016-11-01 2020-02-27 Paratek Pharm Innc 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (cabp)
RU2632708C1 (ru) * 2016-11-14 2017-10-09 Лонг Шенг Фарма Лимитед Способ получения комбинированного антибактериального препарата
CN113164456A (zh) 2018-09-04 2021-07-23 帕拉特克药品公司 使用四环素化合物治疗分枝杆菌感染的方法
CN111484424B (zh) * 2020-04-14 2022-10-25 成都百特万合医药科技有限公司 一种合成奥马环素的方法
JP2023530415A (ja) * 2020-06-11 2023-07-18 パラテック ファーマシューティカルズ，インコーポレイテッド オマダサイクリンの結晶形態、その合成方法及びその使用方法
PT117254B (pt) 2021-05-26 2024-04-18 Hovione Farm S A Método de síntese de compostos 9-aminometil tetraciclinas
CN113433249B (zh) * 2021-07-21 2023-03-24 河北圣雪大成制药有限责任公司 一种高效液相色谱法检测米诺环素中间体有关物质的方法
CN113929593B (zh) * 2021-09-02 2024-05-31 河北圣雪大成唐山制药有限责任公司 一种土霉素-2,5-二羟基苯甲酸共晶及其制备方法
WO2023047323A1 (en) * 2021-09-24 2023-03-30 Glenmark Life Sciences Limited Process for the preparation of omadacycline tosylate
CN119751292A (zh) * 2024-12-30 2025-04-04 重庆圣华曦药业股份有限公司 一种甲苯磺酸奥玛环素的精制方法

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2990331A (en) 1956-11-23 1961-06-27 Pfizer & Co C Stable solutions of salts of tetracyclines for parenteral administration
US2980584A (en) 1957-10-29 1961-04-18 Pfizer & Co C Parenteral magnesium oxytetracycline acetic or lactic acid carboxamide vehicle preparation
US3062717A (en) 1958-12-11 1962-11-06 Pfizer & Co C Intramuscular calcium tetracycline acetic or lactic acid carboxamide vehicle preparation
US3019260A (en) 1959-05-13 1962-01-30 American Cyanamid Co Process for the catalytic reduction of 6-hydroxy hydronaphthacenes
FR1430859A (es) 1960-05-23 1966-05-25
US3165531A (en) 1962-03-08 1965-01-12 Pfizer & Co C 13-substituted-6-deoxytetracyclines and process utilizing the same
DK122658B (da) * 1963-06-17 1972-03-27 Novo Terapeutisk Labor As Fremgangsmåde til udfældning af tetracyclinbase i krystallinsk form.
US3454697A (en) 1965-06-08 1969-07-08 American Cyanamid Co Tetracycline antibiotic compositions for oral use
US3304227A (en) 1965-07-15 1967-02-14 Loyal E Loveless Antibiotic-containing animal feed
NL6607516A (es) 1966-05-31 1967-12-01
DE1767891C3 (de) 1968-06-28 1980-10-30 Pfizer Verfahren zur Herstellung von wäßrigen arzneilichen Lösungen für die parenterale, perorale und lokale Anwendung mit einem Gehalt an einem Tetracyclinderivat
NL158172B (nl) * 1972-09-18 1978-10-16 Farmaceutici Italia Werkwijze voor het bereiden van tetracyclinederivaten met een substituent op de 7-plaats.
US3957980A (en) 1972-10-26 1976-05-18 Pfizer Inc. Doxycycline parenteral compositions
DE2442829A1 (de) 1974-09-06 1976-03-18 Merck Patent Gmbh Tetracyclische verbindungen und verfahren zu ihrer herstellung
US4018889A (en) 1976-01-02 1977-04-19 Pfizer Inc. Oxytetracycline compositions
US4126680A (en) 1977-04-27 1978-11-21 Pfizer Inc. Tetracycline antibiotic compositions
USRE34656E (en) 1983-12-29 1994-07-05 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of bone deficiency
US4935412A (en) 1983-12-29 1990-06-19 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
US4704383A (en) 1983-12-29 1987-11-03 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
US4925833A (en) 1983-12-29 1990-05-15 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis
US4666897A (en) 1983-12-29 1987-05-19 Research Foundation Of State University Inhibition of mammalian collagenolytic enzymes by tetracyclines
US5308839A (en) 1989-12-04 1994-05-03 The Research Foundation Of State University Of New York Composition comprising non-steroidal anti-inflammatory agent tenidap and effectively non-antibacterial tetracycline
JP3016587B2 (ja) 1989-12-04 2000-03-06 ザ・リサーチ・ファンデーション・オブ・ステート・ユニバーシティ・オブ・ニューヨーク 非ステロイド抗炎症剤及びテトラサイクリンの配合
DE4042402C1 (es) 1990-10-03 1992-09-03 Degussa Ag, 6000 Frankfurt, De
US5770588A (en) 1991-02-11 1998-06-23 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions of the prevention and treatment of root caries
US5231017A (en) 1991-05-17 1993-07-27 Solvay Enzymes, Inc. Process for producing ethanol
EP0536515B1 (en) 1991-10-04 2001-12-19 American Cyanamid Company Novel 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
US5494903A (en) 1991-10-04 1996-02-27 American Cyanamid Company 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
US5258371A (en) 1992-05-29 1993-11-02 Kuraray Co., Ltd. Method to reduce connective tissue destruction
US6043225A (en) 1992-06-12 2000-03-28 Board Of Regents Of The University Of Washington Diagnosis and treatment of arterial chlamydial granuloma
JPH06256280A (ja) 1992-11-17 1994-09-13 Univ New York State 糖尿病における過度のコラーゲン架橋結合を阻害する非抗菌性化学修飾テトラサイクリンを含むテトラサイクリン
US5523297A (en) 1993-03-02 1996-06-04 The Research Foundation Of State University Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
US6043231A (en) 1993-03-02 2000-03-28 The Research Foundation Of State Univ. Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
US5668122A (en) 1993-07-28 1997-09-16 Fife; Rose S. Method to treat cancer with tetracyclines
CA2183565A1 (en) 1994-02-17 1995-08-24 Wei-Guo Su 9-(substituted amino)-alpha-6-deoxy-5-oxy tetracycline derivatives, their preparation and their use as antibiotics
US5843925A (en) 1994-12-13 1998-12-01 American Cyanamid Company Methods for inhibiting angiogenesis, proliferation of endothelial or tumor cells and tumor growth
US5834449A (en) 1996-06-13 1998-11-10 The Research Foundation Of State University Of New York Treatment of aortic and vascular aneurysms with tetracycline compounds
US5827840A (en) 1996-08-01 1998-10-27 The Research Foundation Of State University Of New York Promotion of wound healing by chemically-modified tetracyclines
US5789395A (en) 1996-08-30 1998-08-04 The Research Foundation Of State University Of New York Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
US5919774A (en) 1996-12-10 1999-07-06 Eli Lilly And Company Pyrroles as sPLA2 inhibitors
US5837696A (en) 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth
US5773430A (en) 1997-03-13 1998-06-30 Research Foundation Of State University Of New York Serine proteinase inhibitory activity by hydrophobic tetracycline
US6277067B1 (en) 1997-04-04 2001-08-21 Kerry L. Blair Method and portable colposcope useful in cervical cancer detection
US5929055A (en) 1997-06-23 1999-07-27 The Research Foundation Of State University Of New York Therapeutic method for management of diabetes mellitus
US6277061B1 (en) * 1998-03-31 2001-08-21 The Research Foundation Of State University Of New York Method of inhibiting membrane-type matrix metalloproteinase
US6015804A (en) 1998-09-11 2000-01-18 The Research Foundation Of State University Of New York Method of using tetracycline compounds to enhance interleukin-10 production
US5977091A (en) 1998-09-21 1999-11-02 The Research Foundation Of State University Of New York Method of preventing acute lung injury
US5998390A (en) 1998-09-28 1999-12-07 The Research Foundation Of State University Of New York Combination of bisphosphonate and tetracycline
JP5060685B2 (ja) 1998-11-18 2012-10-31 ガルデマ ラボラトリーズ インコーポレイテッド 新規４−デジメチルアミノテトラサイクリン誘導体
DE19938198A1 (de) * 1999-08-12 2001-03-01 Deutsche Telekom Ag Verfahren zum Etablieren eines gemeinsamen Schlüssels für eine Gruppe von mindestens drei Teilnehmern
US6231894B1 (en) 1999-10-21 2001-05-15 Duke University Treatments based on discovery that nitric oxide synthase is a paraquat diaphorase
US7231517B1 (en) * 2000-03-03 2007-06-12 Novell, Inc. Apparatus and method for automatically authenticating a network client
AU8638801A (en) * 2000-07-07 2002-01-21 Tufts College 9-substituted minocycline compounds
AU7164201A (en) * 2000-07-07 2002-01-21 Tufts College 7-substituted tetracycline compounds
US7553828B2 (en) 2001-03-13 2009-06-30 Paratek Pharmaceuticals, Inc. 9-aminomethyl substituted minocycline compounds
EP1955996A1 (en) 2001-03-13 2008-08-13 Paratek Pharmaceuticals, Inc. 7, 9-Substituted tetracycline compounds
US20030021841A1 (en) * 2001-07-02 2003-01-30 Matharu Amol Singh Pharmaceutical composition
CN101307017A (zh) 2002-03-08 2008-11-19 帕拉特克药品公司 氨基-甲基取代的四环素类化合物
JP4099039B2 (ja) * 2002-11-15 2008-06-11 松下電器産業株式会社 プログラム更新方法
US20060287283A1 (en) * 2003-07-09 2006-12-21 Paratek Pharmaceuticals, Inc. Prodrugs of 9-aminomethyl tetracycline compounds
JP4712325B2 (ja) * 2003-09-12 2011-06-29 株式会社リコー 通信装置、通信システム、通信方法及びプログラム
US8015399B2 (en) * 2003-09-30 2011-09-06 Ricoh Company, Ltd. Communication apparatus, communication system, certificate transmission method and program
WO2005101727A1 (ja) * 2004-04-15 2005-10-27 Matsushita Electric Industrial Co., Ltd. 通信装置、通信システム及び認証方法
AR057649A1 (es) * 2005-05-27 2007-12-12 Wyeth Corp Formas solidas cristalinas de tigeciclina y metodos para preparar las mismas
CA2639406A1 (en) * 2006-01-24 2007-08-02 Paratek Pharmaceuticals, Inc. Methods of increasing oral bioavailability of tetracyclines
PT2016045E (pt) * 2006-04-24 2015-02-05 Teva Pharma Forma cristalina de tigeciclina e processos para a sua preparação
CN101134733A (zh) * 2007-09-24 2008-03-05 合肥信风科技开发有限公司 一种替加环素的物质形态及其制备方法
BRPI0908951A2 (pt) * 2008-03-05 2017-01-17 Paratek Pharm Innc compostos de minociclina e método de uso dos mesmos
PT2271348T (pt) * 2008-03-28 2018-04-16 Paratek Pharm Innc Formulação de comprimido oral de composto de tetraciclina
TW202332671A (zh) * 2008-05-19 2023-08-16 美商Ｐｒｔｋ Ｓｐｖ２公司 四環素化合物之甲苯磺酸鹽及同素異形體

Also Published As

Publication number Publication date
ZA201400281B (en) 2015-04-29
AU2009248795B2 (en) 2016-08-25
RU2010152758A (ru) 2012-06-27
CA2724897A1 (en) 2009-11-26
EP2807926A1 (en) 2014-12-03
CN102105058B (zh) 2015-11-25
TW202332671A (zh) 2023-08-16
JP2024169444A (ja) 2024-12-05
HUE053038T2 (hu) 2021-06-28
PL2296464T3 (pl) 2015-08-31
CY1123705T1 (el) 2022-03-24
JP2015166350A (ja) 2015-09-24
JP2022189916A (ja) 2022-12-22
PT2296464E (pt) 2015-07-13
HRP20202081T1 (hr) 2021-02-19
JP5727930B2 (ja) 2015-06-03
US20160324879A1 (en) 2016-11-10
LT2807926T (lt) 2021-02-10
CA2724897C (en) 2017-12-19
US20140005420A1 (en) 2014-01-02
MY156254A (en) 2016-01-29
ECSP10010704A (es) 2011-01-31
ES2842204T3 (es) 2021-07-13
JP2011520988A (ja) 2011-07-21
EP2296464B1 (en) 2015-03-04
KR20110022619A (ko) 2011-03-07
BRPI0913026B1 (pt) 2022-03-03
AU2016262682B2 (en) 2018-06-28
JP2017149750A (ja) 2017-08-31
TW202436282A (zh) 2024-09-16
PL2807926T3 (pl) 2021-05-31
ES2538364T3 (es) 2015-06-19
EP2296464A4 (en) 2011-05-18
TWI680117B (zh) 2019-12-21
TW202021946A (zh) 2020-06-16
BRPI0913026A2 (pt) 2019-08-27
CN108324722A (zh) 2018-07-27
SI2296464T1 (sl) 2015-07-31
JP6129235B2 (ja) 2017-05-17
TW201741281A (zh) 2017-12-01
HRP20150584T1 (hr) 2015-07-03
PT2807926T (pt) 2021-01-12
CA2987354A1 (en) 2009-11-26
TN2010000539A1 (en) 2012-05-24
TW201000433A (en) 2010-01-01
IL209414A0 (en) 2011-01-31
EP3827817A1 (en) 2021-06-02
US20180104262A1 (en) 2018-04-19
KR101679362B1 (ko) 2016-11-25
WO2009143509A1 (en) 2009-11-26
CO6300898A2 (es) 2011-07-21
CY1116436T1 (el) 2017-02-08
TWI585071B (zh) 2017-06-01
US20100113399A1 (en) 2010-05-06
EP2807926B1 (en) 2020-10-07
CN105348138A (zh) 2016-02-24
AU2009248795A1 (en) 2009-11-26
MX2010012622A (es) 2010-12-21
DK2296464T3 (en) 2015-06-15
DK2807926T3 (da) 2021-01-11
JP2021011498A (ja) 2021-02-04
JP2019052184A (ja) 2019-04-04
CN104844472A (zh) 2015-08-19
EP2296464A1 (en) 2011-03-23
CN104844472B (zh) 2018-02-13
RU2500665C2 (ru) 2013-12-10
US9227921B2 (en) 2016-01-05
HK1154757A1 (en) 2012-05-04
AU2016262682A1 (en) 2016-12-15
NZ598154A (en) 2013-05-31
CN102105058A (zh) 2011-06-22
US8383610B2 (en) 2013-02-26
SI2807926T1 (sl) 2021-03-31
MA32407B1 (fr) 2011-06-01
HK1204526A1 (en) 2015-11-27
TW202216656A (zh) 2022-05-01
NZ589574A (en) 2012-04-27
ZA201008390B (en) 2014-03-26

Similar Documents

Publication Publication Date Title
AR075447A1 (es) Sales y polimorfos de un compuesto de tetraciclina, metodo de obtencion y composiciones farmaceuticas
AR126701A1 (es) Derivados de n-ciclopropilpirido[4,3-d]pirimidin-4-amina y usos de los mismos
AR082699A1 (es) Sales de fenotiazindiaminio, composicion farmaceutica en base al compuesto y proceso de preparacion del compuesto
CU20110216A7 (es) Derivados aminobutíricos sustituidos como inhibidores de neprilisina
ECSP11011398A (es) Inhibidores de beta-secretasa
CR20120237A (es) Derivados del ácido carbamoil-metil-amino-acético sustituido como inhibidores de nep novedosos
AR082499A1 (es) Compuestos utiles para trastornos del sistema nervioso, inflamatorios, estomacales y como analgesicos
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
PE20201165A1 (es) Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
UY33731A (es) ?derivados de ácido amino-fenil-pentanoico sustituidos como inhibidores de nep?
CY1122182T1 (el) Ανοσοκατασταλτικες φαρμακοτεχνικες μορφες
AR064304A1 (es) Formulaciones de ansamicina y sus metodos de uso
UY31164A1 (es) Nuevos derivados de bencimidazol, composiciones farmacéuticas conteniéndolos y aplicaciones
AR078164A1 (es) Derivados de isoxazolidina, proceso para preparar dichos compuestos y composiciones farmaceuticas que los comprenden
UY31870A (es) Receptor metabotrópico de glutamato potenciadores 286
CR20150419A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
RU2015125591A (ru) БЕНЗИЛСУЛЬФОНАМИДНЫЕ ПРОИЗВОДНЫЕ КАК МОДУЛЯТОРЫ RORc
AR073769A1 (es) Inhibidores de la integrasa del vih derivados de azepina y oxazepinas condensadas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de infecciones por vih.
CO6781541A2 (es) Derivados glucósidos y usos de los mismos
UY29312A1 (es) Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones
MX2019004941A (es) Formulacion liposomal.
CU20190029A7 (es) Compuestos de aza-indazol útiles en lesiones de tendones y/o ligamentos
CU20190042A7 (es) Compuestos derivados de naftiridinona
CO6321280A2 (es) Nueva clase espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
MX376307B (es) Derivados de oxazetidina, proceso para su preparacion y uso de los mismos en medicina humana y en cosmetica.

Legal Events

Date Code Title Description
FC Refusal